Literature DB >> 15546887

Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells.

Jun Imai1, Hironori Hasegawa, Mikako Maruya, Shigeo Koyasu, Ichiro Yahara.   

Abstract

Antigen cross-presentation is critical in infectious and tumor immunity where cytotoxic T lymphocytes are induced by dendritic cells specifically equipped with cellular machineries to present exogenous antigens with major histocompatibility complex (MHC) class I molecules. To examine molecular mechanisms of antigen cross-presentation, we employed as a model system a murine dendritic cell line DC2.4 capable of presenting soluble antigens such as ovalbumin (OVA) with MHC class I. Here, we demonstrate that exogenously added OVA is accumulated in the endoplasmic reticulum (ER) and late endosomes followed by retrograde transport to the cytoplasm through the Sec61 transporter complexes, and that CHIP functions as an E3 ubiquitin-ligase for OVA degradation by proteasomes. This mechanism is essentially the same as that known as the ER-associated degradation (ERAD) in the quality control of secretary and membrane proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546887     DOI: 10.1093/intimm/dxh184

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  43 in total

1.  Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized.

Authors:  Hu Liu; Shuang Geng; Bo Wang; Bing Wu; Xiaoping Xie; Shuang Wang; Yiwei Zhong; Xuanyi Wang; Di Qu; Yumei Wen; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.

Authors:  Leonia Bozzacco; Christine Trumpfheller; Frederick P Siegal; Saurabh Mehandru; Martin Markowitz; Mary Carrington; Michel C Nussenzweig; Angela Granelli Piperno; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Ubiquitin ligases, critical mediators of endoplasmic reticulum-associated degradation.

Authors:  Zlatka Kostova; Yien Che Tsai; Allan M Weissman
Journal:  Semin Cell Dev Biol       Date:  2007-09-08       Impact factor: 7.727

4.  Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells.

Authors:  Alessandra Giodini; Christoph Rahner; Peter Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

Review 5.  Antigen recognition and presentation by dendritic cells.

Authors:  Kayo Inaba; Muneo Inaba
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 6.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

7.  Chemokine programming dendritic cell antigen response: part I - select chemokine programming of antigen uptake even after maturation.

Authors:  Jaehyung Park; Cindy T Wu; James D Bryers
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397

8.  Purification of the Membrane Compartment for Endoplasmic Reticulum-associated Degradation of Exogenous Antigens in Cross-presentation.

Authors:  Jun Imai; Mayu Otani; Takahiro Sakai; Shinichi Hatta
Journal:  J Vis Exp       Date:  2017-08-21       Impact factor: 1.355

9.  Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.

Authors:  Renato B Baleeiro; René Rietscher; Andrea Diedrich; Justyna A Czaplewska; Claus-Michael Lehr; Regina Scherließ; Andrea Hanefeld; Michael Gottschaldt; Peter Walden
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

Review 10.  MHC class I assembly: out and about.

Authors:  Malini Raghavan; Natasha Del Cid; Syed Monem Rizvi; Larry Robert Peters
Journal:  Trends Immunol       Date:  2008-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.